CEBPA mutation in acute myeloid leukemia: prognostic impact of bZIP domain mutation

[1] Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998; 18: 4301–4314. RadomskaHS HuettnerCS ZhangP ChengT ScaddenDT TenenDG CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors Mol Cell Biol 1998 18 4301 4314 Search in Google Scholar

[2] Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al; Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. LeyTJ MillerC DingL RaphaelBJ MungallAJ RobertsonA Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N Engl J Med 2013 368 22 2059 2074 Search in Google Scholar

[3] Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221. PapaemmanuilE GerstungM BullingerL GaidzikVI PaschkaP RobertsND Genomic classification and prognosis in acute myeloid leukemia N Engl J Med 2016 374 23 2209 2221 Search in Google Scholar

[4] Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200–1228. doi: 10.1182/blood.2022015850. PMID: 35767897; PMCID: PMC9479031. ArberDA OraziA HasserjianRP BorowitzMJ CalvoKR KvasnickaHM International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data Blood 2022 Sep 15 140 11 1200 1228 10.1182/blood.2022015850 35767897 PMC9479031 Open DOISearch in Google Scholar

[5] Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022 Jul;36(7):1703–1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22. PMID: 35732831; PMCID: PMC9252913. KhouryJD SolaryE AblaO AkkariY AlaggioR ApperleyJF The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms Leukemia 2022 Jul 36 7 1703 1719 10.1038/s41375-022-01613-1 Epub 2022 Jun 22. 35732831 PMC9252913 Open DOISearch in Google Scholar

[6] Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):eaan4673. JaiswalS EbertBL Clonal hematopoiesis in human aging and disease Science 2019 366 6465 eaan4673 Search in Google Scholar

[7] Hartmut Döhner, Andrew H. Wei, Frederick R. Appelbaum, Charles Craddock, Courtney D. DiNardo, Hervé Dombret, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140 (12): 1345–1377. doi: https://doi.org/10.1182/blood.2022016867. DöhnerHartmut WeiAndrew H. AppelbaumFrederick R. CraddockCharles DiNardoCourtney D. DombretHervé Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN Blood 2022 140 12 1345 1377 doi: https://doi.org/10.1182/blood.2022016867. Search in Google Scholar

[8] Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, € define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088–3091. WoutersBJ LowenbergB Erpelinck-VerschuerenCA van PuttenWL ValkPJ DelwelR Double CEBPA mutations, but not single CEBPA mutations, € define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome Blood 2009 113 13 3088 3091 Search in Google Scholar

[9] Pabst T, Eyholzer M, Fos J, Mueller BU. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer. 2009;100(8):1343–1346. PabstT EyholzerM FosJ MuellerBU Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis Br J Cancer 2009 100 8 1343 1346 Search in Google Scholar

[10] Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28(16):2739–2747. GreenCL KooKK HillsRK BurnettAK LinchDC GaleRE Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations J Clin Oncol 2010 28 16 2739 2747 Search in Google Scholar

[11] Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010 Feb 1;28(4):570–7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28. PMID: 20038735. DufourA SchneiderF MetzelerKH HosterE SchneiderS ZellmeierE Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome J Clin Oncol 2010 Feb 1 28 4 570 7 10.1200/JCO.2008.21.6010 Epub 2009 Dec 28. 20038735 Open DOISearch in Google Scholar

[12] Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117(8):2469–2475. TaskesenE BullingerL CorbaciogluA SandersMA ErpelinckCA WoutersBJ Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity Blood 2011 117 8 2469 2475 Search in Google Scholar

[13] Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood. 2013;122(9):1576–1582. SchlenkRF TaskesenE van NordenY KrauterJ GanserA BullingerL The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA Blood 2013 122 9 1576 1582 Search in Google Scholar

[14] Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Hoboken, NJ: John Wiley & Sons, Inc; 2002. KalbfleischJD PrenticeRL The Statistical Analysis of Failure Time Data Hoboken, NJ John Wiley & Sons, Inc 2002 Search in Google Scholar

[15] Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 2022 Jan 11;6(1):238–247. doi: 10.1182/bloodadvances.2021004292. PMID: 34448807; PMCID: PMC8753195. WakitaS SakaguchiM OhI KakoS ToyaT NajimaY Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia Blood Adv 2022 Jan 11 6 1 238 247 10.1182/bloodadvances.2021004292 34448807 PMC8753195 Open DOISearch in Google Scholar

[16] Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022 Jan 6;139(1):87–103. doi: 10.1182/blood.2020009680. PMID: 34320176. TaubeF GeorgiJA KramerM StasikS MiddekeJM RölligC CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome Blood 2022 Jan 6 139 1 87 103 10.1182/blood.2020009680 34320176 Open DOISearch in Google Scholar

[17] Tarlock K, Lamble AJ, Wang YC, Gerbing RB, Ries RE, Loken MR, et al. CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group. Blood. 2021 Sep 30;138(13):1137–1147. doi: 10.1182/blood.2020009652. Erratum in: Blood. 2022 Mar 10;139(10):1601. PMID: 33951732; PMCID: PMC8570058. TarlockK LambleAJ WangYC GerbingRB RiesRE LokenMR CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group Blood 2021 Sep 30 138 13 1137 1147 10.1182/blood.2020009652 Erratum in: Blood. 2022 Mar 10;139(10):1601. 33951732 PMC8570058 Open DOISearch in Google Scholar

[18] Georgi J-A, Taube F, Kramer M, Herold S, Schaefer-Eckart K, Schmitz N, et al. Differences between CEBPA bZIP and TAD mutations and their effect on outcome-an analysis in 4578 patients with acute myeloid leukemia [abstract]. Blood. 2016;128(22). Abstract 283. GeorgiJ-A TaubeF KramerM HeroldS Schaefer-EckartK SchmitzN Differences between CEBPA bZIP and TAD mutations and their effect on outcome-an analysis in 4578 patients with acute myeloid leukemia [abstract] Blood 2016 128 22 Abstract 283. Search in Google Scholar